Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value

$26.47−2.60 (-8.94%)

Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –

Zymeworks cash

Cash and short-term investments held at the end of each period.

Zymeworks's cash was $100.46M at Sep 30, 2026. For fiscal 2025 it was $41.16M, down 37.7% from the year before. The highest annual figure on record is $492.23M in fiscal 2022.

Annual cash

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$41.16M	-37.7%
FY2024	Dec 31, 2024	$66.10M	-82.3%
FY2023	Dec 31, 2023	$374.33M	-24.0%
FY2022	Dec 31, 2022	$492.23M	+94.9%
FY2021	Dec 31, 2021	$252.61M	+4.4%
FY2020	Dec 31, 2020	$242.04M	+88.4%
FY2019	Dec 31, 2019	$128.45M	–

Quarterly cash

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$100.46M	+55.0%
Q2 FY2026	Jun 30, 2026	$179.41M	+82.6%
Q1 FY2026	Mar 31, 2026	$244.28M	+220.6%
Q4 FY2025	Dec 31, 2025	$41.16M	-37.7%
Q3 FY2025	Sep 30, 2025	$64.83M	-47.0%
Q2 FY2025	Jun 30, 2025	$98.25M	+38.5%
Q1 FY2025	Mar 31, 2025	$76.20M	-33.6%
Q4 FY2024	Dec 31, 2024	$66.10M	-82.3%
Q3 FY2024	Sep 30, 2024	$122.36M	-58.6%
Q2 FY2024	Jun 30, 2024	$70.96M	-79.1%
Q1 FY2024	Mar 31, 2024	$114.81M	-66.3%
Q4 FY2023	Dec 31, 2023	$374.33M	-24.0%
Q3 FY2023	Sep 30, 2023	$295.41M	+77.7%
Q2 FY2023	Jun 30, 2023	$340.09M	+71.2%
Q1 FY2023	Mar 31, 2023	$340.79M	+23.7%
Q4 FY2022	Dec 31, 2022	$492.23M	+94.9%
Q3 FY2022	Sep 30, 2022	$166.24M	-34.4%
Q2 FY2022	Jun 30, 2022	$198.65M	-17.9%
Q1 FY2022	Mar 31, 2022	$275.52M	+114.5%
Q4 FY2021	Dec 31, 2021	$252.61M	–
Q3 FY2021	Sep 30, 2021	$253.44M	–
Q4 FY2020	Dec 31, 2020	$242.04M	–
Q4 FY2019	Dec 31, 2019	$128.45M	–